Compounds > fluorocoxib a
Page last updated: 2024-11-13

fluorocoxib a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

fluorocoxib A: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID24884549
SCHEMBL ID860802
MeSH IDM0582531

Synonyms (3)

Synonym
SCHEMBL860802
fluorocoxib a
5-[4-[[2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetyl]amino]butylcarbamoyl]-2-(3-oxa-23-aza-9-azoniaheptacyclo[17.7.1.15,9.02,17.04,15.023,27.013,28]octacosa-1(27),2(17),4,9(28),13,15,18-heptaen-16-yl)benzoic acid

Research Excerpts

Overview

Fluorocoxib A is a targeted optical imaging agent. It could be applied for the detection of Cox-2 expressing human bladder cancer.

ExcerptReferenceRelevance
"Fluorocoxib A is a targeted optical imaging agent that could be applied for the detection of Cox-2 expressing human bladder cancer."( Detection of carcinogen-induced bladder cancer by fluorocoxib A.
Bourn, J; Cekanova, M; Donnell, R; Marnett, L; Rathore, K; Uddin, MJ; White, W, 2019)		2.21

Toxicity

ExcerptReferenceRelevance
" Blood and urine samples collected three days after administration of each dose of fluorocoxib A revealed no evidence of toxicity, and no clinically relevant adverse events were noted on physical examination of exposed dogs over that time period."( Single-dose safety and pharmacokinetic evaluation of fluorocoxib A: pilot study of novel cyclooxygenase-2-targeted optical imaging agent in a canine model.
Bartges, JW; Callens, A; Cekanova, M; Galyon, G; Legendre, AM; Marnett, LJ; Martin-Jimenez, T; Uddin, MJ, 2012)		0.85

Pharmacokinetics

ExcerptReferenceRelevance
"We evaluated preclinical single-dose safety, pharmacokinetic properties, and specific uptake of the new optical imaging agent fluorocoxib A in dogs."( Single-dose safety and pharmacokinetic evaluation of fluorocoxib A: pilot study of novel cyclooxygenase-2-targeted optical imaging agent in a canine model.
Bartges, JW; Callens, A; Cekanova, M; Galyon, G; Legendre, AM; Marnett, LJ; Martin-Jimenez, T; Uddin, MJ, 2012)		0.83
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (85.71)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.48

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.48 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.48)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
ConditionIndicatedRelationship StrengthStudiesTrials
Adenoma, Basal Cell
[description not available]		02.610
Cancer of Colon
[description not available]		02.610
Colorectal Cancer
[description not available]		02.5720
Adenoma
A benign epithelial tumor with a glandular organization.		07.610
Colonic Neoplasms
Tumors or cancer of the COLON.		02.610
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		02.5720
Carcinogenesis
The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.		02.2110
Bladder Cancer
[description not available]		07.5320
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.2110
B16 Melanoma
[description not available]		02.2110
Urinary Bladder Neoplasms
Tumors or cancer of the URINARY BLADDER.		02.5320
Carcinoma, Transitional Cell
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.		02.0810
Carcinoma, Basal Cell, Pigmented
[description not available]		02.1110
Cancer of Skin
[description not available]		02.1110
Carcinoma, Basal Cell
A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)		02.1110
Skin Neoplasms
Tumors or cancer of the SKIN.		02.1110
Innate Inflammatory Response
[description not available]		02.1310
Benign Neoplasms
[description not available]		02.1310
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		07.1310
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.1310
Choroid Neovascularization
[description not available]		02.1310
Canine Diseases
[description not available]		02.0710